Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dexamethasone 16mg Clear all
Completed Phase 2 Interventional Results available

Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma

NCT03224507
View directory record Official record
Conditions
Multiple Myeloma
Interventions
KRdD followed by auto-HCT, KRdD only
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Birmingham, Alabama • Portland, Oregon • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced Sep 3, 2026, 10:14 PM EDT
Terminated Phase 2 Interventional Results available

Low Dose Aprepitant for Patients Receiving Carboplatin

NCT03237611
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Aprepitant 125 mg, Fosaprepitant 115 MG, Dexamethasone, Ondansetron 16 MG
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 3, 2026, 10:14 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

NCT03290950
View directory record Official record
Conditions
Multiple Myeloma
Interventions
daratumumab, carfilzomib, lenalidomide, dexamethasone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 3, 2026, 10:14 PM EDT
Completed Phase 4 Interventional Results available

Dexamethasone for Migraine - Dose Comparison

NCT04112823
View directory record Official record
Conditions
Migraine
Interventions
Dexamethasone 4mg, Dexamethasone 16mg
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 3, 2026, 10:14 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma

NCT02807454
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Durvalumab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
15
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 3, 2026, 10:14 PM EDT
Completed Phase 1 Interventional

Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)

NCT01724606
View directory record Official record
Conditions
Breast Cancer, Brain Metastases
Interventions
Whole Brain Radiotherapy (WBRT), Sorafenib
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2022 · Synced Sep 3, 2026, 10:14 PM EDT
Withdrawn Phase 2 Interventional

Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy

NCT04223661
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide Pill, Dexamethasone, Daratumumab
Drug
Lead sponsor
Attaya Suvannasankha
Other
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Sep 3, 2026, 10:14 PM EDT
Recruiting Phase 2 Interventional

Pediatric Asthma Trial of Corticosteroid Heterogeneity (PATCH): Trial of Dexamethasone Versus Methylprednisolone for Pediatric Critical Asthma

NCT07455396
View directory record Official record
Conditions
Asthma (Diagnosis)
Interventions
Dexamethasone (0.6mg/kg; Max 16mg) Once Daily, Dexamethasone (0.25 mg/kg/dose, Max dose 16mg) every 6-hours, Methylprednisolone
Drug
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
3 Years to 17 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 3, 2026, 10:14 PM EDT
Enrolling by invitation Phase 4 Interventional

Post-operative Methylprednisolone Taper Course for Orthopedic Surgery

NCT03661645
View directory record Official record
Conditions
Orthopedic Surgeries
Interventions
10 mg IV dexamethasone & 6 day oral methylprednisolone taper, 10 mg IV dexamethasone
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 95 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 3, 2026, 10:14 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

NCT02773030
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CC-220, Dexamethasone, Daratumumab, Bortezomib, Carfilzomib, Daratumumab - 16mg/kg, Bortezomib (BTZ), Daratumumab- 1800mg
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
58
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Atlanta, Georgia + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 3, 2026, 10:14 PM EDT
Terminated Phase 4 Interventional Results available

Perioperative Glucocorticoid Administration in the Treatment of Adult Distal Radius Fractures

NCT03898154
View directory record Official record
Conditions
Distal Radius Fracture
Interventions
Dexamethasone, Methylprednisolone
Drug
Lead sponsor
C. Liam Dwyer
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 3, 2026, 10:14 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

NCT02076009
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
569 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
23
States / cities
Little Rock, Arkansas • Gainesville, Florida • West Palm Beach, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Sep 3, 2026, 10:14 PM EDT
Terminated Phase 2 Interventional Results available

Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors

NCT00609765
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Avastin, Fluorouracil, Doxorubicin, Streptozocin, Dexamethasone, Ondansetron
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 3, 2026, 10:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Dexamethasone in Total Knee Arthroplasty

NCT05018091
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Dexamethasone 4mg, Dexamethasone 8 Mg/mL Injectable Suspension, Dexamethasone 16mg
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
438 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
10
States / cities
Redwood City, California • San Francisco, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 3, 2026, 10:14 PM EDT
Recruiting Phase 4 Interventional

Giving Asthmatics Intramuscular Steroids for Preventing Return to the Emergency Department

NCT07228052
View directory record Official record
Conditions
Asthma
Interventions
Dexamethasone 16mg IM, Prednisone 60mg PO
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 3, 2026, 10:14 PM EDT
Terminated Phase 2 Interventional Results available

Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

NCT00335140
View directory record Official record
Conditions
Lymphoma
Interventions
Rituximab, Cytarabine, Dexamethasone, Leucovorin, Methotrexate, Procarbazine, Vincristine
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
68
States / cities
Stanford, California • Gainesville, Florida • Jacksonville, Florida + 51 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 3, 2026, 10:14 PM EDT
Terminated Phase 2 Interventional

Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma

NCT03590652
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Ixazomib, Pomalidomide, Dexamethasone, Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 3, 2026, 10:14 PM EDT
Enrolling by invitation Phase 4 Interventional

How Many Dexamethasone Doses Should Be Given Perioperatively?

NCT06715709
View directory record Official record
Conditions
Arthropathy of Knee
Interventions
Dexamethasone IV, Dexamethasone IV+Oral, Dexamethasone IV+Oral 2 Day
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 3, 2026, 10:14 PM EDT